Related Experiment Video
Updated: Jun 27, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy
A Gompel1, S Rozenberg, D H Barlow
1University Paris Descartes, APHP, Unité de Gynécologie Endocrinienne, Hôtel-Dieu de Paris, 1 Place Jean-Paul II, Paris 75004, France. anne.gompel@htd.aphp.fr
Abstract:
Hormone therapy is still the most commonly used treatment to relieve menopausal symptoms and the consequences of oestrogen deficiency. The decision process is complex and benefits needs to be balanced vs. risks. Not all reported benefits and risks have been as well highlighted by the media throughout recent years, it is therefore important to update regularly the current scientific knowledge. This is an actualization of the last EMAS statement concerning hormone replacement therapy use.
Related Concept Videos
Menopause
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Standards of Care II
Drug Dosing: Geriatric Patients
Atherosclerosis III: Management
